MEDIVATION, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2015-12-18: Form 8-K/A; Period of report 2015-10-06; Description 9.01 Financial Statements and Exhibits; Details 9.01.
- 2015-12-07: Form 8-K; Period of report 2015-12-04; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2015-11-06: Form 8-K; Period of report 2014-12-19; Description 2.01 Completion of Acquisition or Disposition of Assets; Details 2.01.
- 2015-11-05: Form 8-K; Period of report 2015-11-05; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2015-12-18 | 8-K/A | 2015-10-06 | 9.01 Financial Statements and Exhibits | 9.01 Medivation has concluded that according to the guidance in Financial Accounting Standards Board Accounting Standards Codification Topic No. 805, “Business Combinations,” and Article 11 of Regulation S-X, the transaction meets the definition of a “business” and exceeds the conditions of significance set forth in Rule 1-02(w) of Regulation S-X at the greater than 50% level. | d100084d8ka.htm |
| 2015-12-07 | 8-K | 2015-12-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 4, 2015, Michael L. King, Ph.D. was elected by the board of directors (the “Board”) of Medivation, Inc. as a member of the Board. | d95231d8k.htm |
| 2015-11-06 | 8-K | 2014-12-19 | 2.01 Completion of Acquisition or Disposition of Assets | 2.01 On October 23, 2014, Medivation, Inc. (“Medivation”) entered into a License Agreement with CureTech Ltd. (“CureTech”) pursuant to which Medivation could acquire an exclusive license to the worldwide rights to pidilizumab, an immunomodulatory antibody, for all potential indications. | d63009d8k.htm |
| 2015-11-05 | 8-K | 2015-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2015, Medivation, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2015. | d67417d8k.htm |
| 2015-10-30 | 8-K | 2015-10-29 | 8.01 Other Events | 8.01 On October 30, 2015, in Tokyo, Japan (October 29, 2015, in San Francisco, CA), Medivation, Inc.’s collaboration partner Astellas Pharma Inc. (Astellas), reported its financial results for the quarter ended September 30, 2015. | d43523d8k.htm |
| 2015-10-26 | 8-K | 2015-10-23 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth under Item 1.01, “Entry into a Material Definitive Agreement” is incorporated herein by reference. | d64848d8k.htm |
| 2015-10-07 | 8-K | 2015-10-06 | 2.01 Completion of Acquisition or Disposition of Assets | 2.01 On October 6, 2015, Medivation, Inc. (“Medivation”) completed its acquisition of all rights to talazoparib (MDV3800; formerly referred to as BMN-673) from BioMarin Pharmaceutical Inc. (“BioMarin”) pursuant to the Asset Purchase Agreement entered into between Medivation and BioMarin dated August 21, 2015 (the “Agreement”). | d99291d8k.htm |
| 2015-09-29 | 8-K | 2015-09-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 23, 2015, Lynn Seely, M.D., Medivation, Inc.’s Chief Medical Officer, advised Medivation that she plans to retire from her position at Medivation effective October 15, 2015. | d42675d8k.htm |
| 2015-09-18 | 8-K | 2015-09-17 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 2.03 As previously disclosed in the Current Report on Form 8-K filed by Medivation, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on September 9, 2015, the Company, as borrower, entered into a credit agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders from time to time party thereto, providing for (i) a one-year $75 million revolving loan facility (the “Revolving Credit Facility”); and (ii) an uncommitted accordion facility subject to the satisfaction of certain conditions. | d85218d8k.htm |
| 2015-09-09 | 8-K | 2015-09-04 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d82227d8k.htm |
| 2015-08-24 | 8-K | 2015-08-21 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 7.01 On August 24, 2015, Medivation and BioMarin issued a joint press release announcing the entry into the Agreement. | d86752d8k.htm |
| 2015-08-06 | 8-K | 2015-08-06 | 2.02 Results of Operations and Financial Condition | 2.02 On August 6, 2015, Medivation, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2015. | d27117d8k.htm |
| 2015-07-31 | 8-K | 2015-07-30 | 8.01 Other Events | 8.01 On July 31, 2015, in Tokyo, Japan (July 30, 2015, in San Francisco, CA), Medivation, Inc.’s alliance partner Astellas Pharma Inc., reported its financial results for the quarter ended June 30, 2015. | d87411d8k.htm |
| 2015-06-19 | 8-K | 2015-06-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 The annual meeting of stockholders of Medivation, Inc. was held on June 16, 2015 (the “Annual Meeting”). 5.07 The Annual Meeting was held on June 16, 2015, and five proposals were submitted to the Medivation stockholders for a vote. | d944606d8k.htm |
| 2015-06-19 | 8-K | 2015-06-19 | 7.01 Regulation FD Disclosure | 7.01 On June 19, 2015, Medivation, Inc. (the “Company”), announced the redemption of all of its outstanding 2.625% Convertible Notes due 2017. | d945492d8k.htm |
| 2015-05-28 | 8-K | 2015-05-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 28, 2015, Medivation, Inc. announced the appointment of Andrew K. W. Powell as Senior Vice President, General Counsel and Corporate Secretary of Medivation, effective May 27, 2015. | d934805d8k.htm |
| 2015-05-07 | 8-K | 2015-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2015, Medivation, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2015. | d924815d8k.htm |
| 2015-02-25 | 8-K | 2015-02-25 | 2.02 Results of Operations and Financial Condition | 2.02 On February 25, 2015, Medivation, Inc. (the “Company”) announced its financial results for the fourth quarter and fiscal year ended December 31, 2014. | d881206d8k.htm |
| 2015-02-13 | 8-K | 2015-02-09 | 3.03 Material Modification to Rights of Security Holders; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 3.03 On February 9, 2015, the Board of Directors of Medivation, Inc. (the “Company”) amended Section 44 of the Company’s Amended and Restated Bylaws (the “Bylaws”) to reduce the threshold for stockholder approval to amend the Bylaws from 66 2/3% of the voting power of all of the outstanding shares of the capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class, to a majority of the voting power of all of the outstanding shares of the capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class. 5.02 On February 9, 2015, the Compensation Committee of the Board of Directors (the “Committee”) of the Company approved cash bonuses for the Company’s executive officers pursuant to the Company’s 2014 Bonus Plan, in recognition of both the level of the Company’s achievement of its corporate goals for 2014 and each executive officer’s contributions toward the achievement of those goals. 5.03 Reference is made to the disclosure set forth under Item 3.03 above, which disclosure is incorporated by reference here. | d873637d8k.htm |
| 2015-02-02 | 8-K | 2015-02-01 | 2.02 Results of Operations and Financial Condition | 2.02 On February 2, 2015 in Tokyo, Japan (February 1, 2015 in San Francisco, CA), Medivation, Inc.’s alliance partner Astellas Pharma Inc., reported its financial results for the quarter ended December 31, 2014. | d862109d8k.htm |